EUVIMEDEUVIMED entdecken
EditorialKommentar

Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis

Mark O Wielpütz iD, Marcus A Mall iD

European Respiratory Journal · 2024

DOI: 10.1183/13993003.00234-2024 ↗

Kurz gefasst

Editorial in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Mark O Wielpütz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany Mark.Wielpuetz@med.uni-heidelberg.de. Hauptthemen laut MEDLINE: Cystic Fibrosis, Bronchiectasis, Benzodioxoles, Indoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Shareable abstract The study by Cazier and co-workers promotes current efforts to diagnose and treat CF lung disease as early as possible in order to prevent structural lung damage, and to target initially reversible changes before persistent airway damage is establishedhttps://bit.ly/42K7tYW

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBronchiectasisBenzodioxolesIndolesAminophenolsPyrazolesPyridinesPyrrolidinesQuinolonesAdultHumansCystic Fibrosis Transmembrane Conductance RegulatorDilatation

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorivacaftorelexacaftortezacaftorCFTR protein, humanBenzodioxolesIndolesAminophenolsPyrazolesPyridines

Autor:innen und Institutionen

  • Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany Mark.Wielpuetz@med.uni-heidelberg.de.
  • Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
  • Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany.
  • Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • German Center for Lung Research (DZL), associated partner site, Berlin, Germany.
  • Berlin Institute of Health (BIH) at Charité-Universitätsmedizin Berlin, Berlin, Germany.

ORCID-Profile: Mark O Wielpütz, Marcus A Mall

Zitieren

APA

Wielpütz, M. O., & Mall, M. A. (2024). Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis. European Respiratory Journal. https://doi.org/10.1183/13993003.00234-2024

Vancouver

Wielpütz MO, Mall MA. Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis. European Respiratory Journal. 2024. doi:10.1183/13993003.00234-2024

BibTeX
@article{Wielptz2024,
  author = {Wielpütz, Mark O and Mall, Marcus A},
  title = {Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis},
  journal = {European Respiratory Journal},
  year = {2024},
  doi = {10.1183/13993003.00234-2024}
}
Kostenlos starten →